Any feedback?
Literature summary for 1.8.1.9 extracted from
- Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase (2008), Cancer Lett., 260, 127-136.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | both pharmacological and toxicological effects of anti-cancer drug cisplatin involve TrxR inactivation, and the large enhancement on cisplatin cure rate in H22 ascites model by using amifostine is, at least in part, ascribed to its selective modulation on TrxR | Mus musculus |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| cisplatin | at pharmacological doses inhibits TrxR activity in both ascitic hepatoma 22 cells and kidney, leading to suppression of H22 cells proliferation along with nephrotoxicity. Amifostine, a clinical used cytoprotective agent, protected against CDDP-induced TrxR inactivation in kidney but not in H22 cells | Mus musculus |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Mus musculus | - |
male Kunming mice | - |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| TrxR | - |
Mus musculus |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
